VF
TOVX icon

Virtu Financial’s Theriva Biologics TOVX Stock Holding History

Virtu Financial’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22K Sell
87,138
-166,080
-66% -$49.2K ﹤0.01% 1338
2026
Q1 		$50K Buy
+253,218
New +$49.9K ﹤0.01% 1291
2025
Q4 		– Sell
-36,781
Closed -$15K – 2240
2025
Q3 		$15K Buy
36,781
+2,286
+7% +$989 ﹤0.01% 1308
2025
Q2 		$15K Buy
+34,495
New +$28K ﹤0.01% 1286
2024
Q1 		– Sell
-1,565
Closed -$17K – 2102
2023
Q4 		$17K Buy
+1,565
New +$19.3K ﹤0.01% 1344
2023
Q1 		– Sell
-1,159
Closed -$13K – 2102
2022
Q4 		$13K Buy
1,159
+661
+133% +$12K ﹤0.01% 1348
2022
Q3 		$12K Buy
+498
New +$19.1K ﹤0.01% 1497
2022
Q2 		– Sell
-1,226
Closed -$87K – 2078
2022
Q1 		$87K Sell
1,226
-100
-8% -$6.81K 0.01% 1006
2021
Q4 		$90K Buy
1,326
+557
+72% +$52.5K 0.01% 1173
2021
Q3 		$88K Sell
769
-231
-23% -$28.7K 0.01% 1179
2021
Q2 		$151K Sell
1,000
-867
-46% -$124K 0.01% 1093
2021
Q1 		$318K Buy
1,867
+1,449
+347% +$286K 0.02% 783
2020
Q4 		$40K Buy
+418
New +$36.6K ﹤0.01% 1265
2019
Q2 		– Sell
-376
Closed -$64K – 1869
2019
Q1 		$64K Buy
376
+327
+667% +$54.2K ﹤0.01% 1186
2018
Q4 		$7K Sell
49
-86
-64% -$20.4K ﹤0.01% 1466
2018
Q3 		$88K Buy
+135
New +$149K 0.01% 1216
2018
Q2 		– Sell
-1
Closed -$4K – 2503
2018
Q1 		$4K Sell
1
-33
-97% -$125K ﹤0.01% 1871
2017
Q4 		$152K Buy
34
+24
+240% +$150K 0.01% 1785
2017
Q3 		$79K Buy
+10
New +$57.8K ﹤0.01% 2129

Other funds holding TOVX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return

Virtu Financial's TOVX Position: Q2 2026 in Review

Virtu Financial reduced its Theriva Biologics (TOVX) stake by 66% in Q2 2026, selling an estimated $49.2K and leaving 87,138 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #1338.

Virtu Financial first reported a position in TOVX in Q3 2017 and has held it in 19 quarters since. The position peaked at $318K in Q1 2021. 26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

  • Virtu Financial held 87,138 shares of Theriva Biologics worth $22K as of Q2 2026.
  • Virtu Financial sold 166,080 Theriva Biologics shares in Q2 2026, an estimated $49.2K.
  • Theriva Biologics made up ﹤0.01% of Virtu Financial's portfolio in Q2 2026, its #1338 holding.
  • Virtu Financial first reported a position in Theriva Biologics in Q3 2017 and has held it in 19 quarters since.
  • Virtu Financial's Theriva Biologics position peaked at $318K in Q1 2021.
  • 26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.